southwestforests
Senior Member
- Messages
- 1,561
- Location
- Missouri
Just saw this via a Tumblr post by an Irish guy who has ME/CFS.
The post,
Direct link to newspaper article mentioned in post,
https://www.irishtimes.com/health/y...lanation-for-this-long-misunderstood-illness/
The post,
Direct link to newspaper article mentioned in post,
https://www.irishtimes.com/health/y...lanation-for-this-long-misunderstood-illness/
Now, in his book, Understanding ME/CFS & Strategies for Healing (2025), Irish author Patrick Ussher not only adds compelling insights to the burgeoning evidence base for ME’s physical origins, but also outlines a unifying model for ME, highlighting research towards possible effective treatment.
He adds: “For ME to make sense as an illness, it cannot be random: it must follow certain physiological laws.”
These physiological laws inform the evolution of Wirth and Scheibenbogen’s unifying model hypothesis, which inter alia considers a key role for autoantibodies against blood flow-related cellular receptors in skeletal muscle and the brain; the mechanisms by which ME patients develop low blood volume and systemic blood hypoperfusion (a reduced amount of blood flow); and the contribution of high muscle sodium and calcium concentrations to mitochondrial dysfunction and muscle-tissue necrosis.
The refinement of Wirth and Scheibenbogen’s unifying model hypothesis has led to a therapeutic concept: a drug called Mitodicure, which is “a novel molecule to treat patients with exertional intolerance and post-exertional malaise (PEM)”. Steps are under way to attract funding for clinical trials.
Mitodicure, says Ussher, “could represent the long-awaited breakthrough treatment for ME and Long Covid. Its mechanism of action will interrupt several key vicious cycles at once, particularly targeting the mechanisms underlying PEM.
“During symptom exacerbations of PEM,” he explains, “most illness mechanisms heighten and intensify. By preventing PEM, Mitodicure could relieve physiological burdens, enabling the body to concentrate its resources on healing.
“Mitodicure is not symptom suppression,” Ussher emphasises, “Prof Wirth considers Mitodicure to represent a potential cure for these illnesses.”
Cautiously optimistic, Ussher suggests that Mitodicure could demystify ME: “If you have a therapeutic based on a certain disease model and it works as hypothesised, the disease model is also validated. The pill can prove the principle. So Mitodicure could offer not only improved quality of life (or better) but could also advance our understanding of ME.”
Although Ussher’s enthusiasm is tempered with an acute awareness of the need for scientific rigour, his approach to science appears sceptical towards the exalted status of stored facts and may align with Mary Midgley’s view that stored facts are “valueless unless you know how to use them, how to connect them with other things, how to understand them”. Ussher’s book represents an interpretative scheme; a vehicle, as he puts it, “for raising awareness of Wirth and Scheibenbogen’s ‘unifying model’ of ME and the potential Mitodicure pill which is based on it”.